

EXHIBIT C2

Medical Drug Recommendations to ASE/PSE Commission

March 2025

Drug	Treating Diagnosis	EBD Recommendation (based on input from EBRx)	Comment	Cost	Commission Decision	Board of Finance Decision
Yesintek	Targeted Immunomodulator	Cover with EBRx PA	Low cost Stelara biosimilar. Covering to match pharmacy benefit.	WAC \$1,499 every 12 weeks	Approve Recommendation	Approve Recommendation
Steqeyma	Targeted Immunomodulator	Cover with EBRx PA	Low cost Stelara biosimilar. Covering to match pharmacy benefit.	WAC \$2,087 every 12 weeks	Approve Recommendation	Approve Recommendation
Selarsdi	Targeted Immunomodulator	Cover with EBRx PA	Low cost Stelara biosimilar. Covering to match pharmacy benefit.	WAC \$2,088 every 12 weeks	Approve Recommendation	Approve Recommendation
Wezlana	Targeted Immunomodulator	Exclude	Middle cost Stelara biosimilar. Excluding to match pharmacy benefit.	WAC \$2,784 every 12 weeks	Approve Recommendation	Approve Recommendation
Opdivo Qvantiq	Numerous cancers	Cover with EBRx PA	New formulation of Opdivo with a 3-5 min injection. Will continue with the same PA criteria for Opdivo IV.	\$18,690 per 28 days (same as Opdivo IV)	Approve Recommendation	Approve Recommendation
Alhemo	Prophylaxis of Hemophilia A & B	Exclude	Covered alternative is Hemlibra	Dose/cost based on response, <\$2M per yr	Approve Recommendation	Approve Recommendation
Datroway	Breast cancer	Exclude	Did not improve overall survival	\$443,696 per year	Approve Recommendation	Approve Recommendation
Axtle	Numerous cancers	Exclude	Covered alternative is reconstituted pemetrexed disodium	\$8,295 per dose	Approve Recommendation	Approve Recommendation
Radicava (IV)	ALS	Exclude	While it extends survival, it does not improve QOL. Lifetime grandfather of impacted members.	\$9,750 per month	Approve Recommendation	Approve Recommendation

NTM = new to market, No EBRx Restrictions means that policy defers to Health Advantage, WAC = Wholesale Acquisition Cost